Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies

PLoS ONE

Volumn 13, Issue 6, 2018, Pages

  Olive, Jessica F ^a,b   Qin, Yuanbo ^a,b   DeCristo, Molly J ^a,b   Laszewski, Tyler ^a   Greathouse, Frances ^a   McAllister, Sandra S ^a,b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; OSTEOPONTIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA CELL LINE; CANCER GROWTH; CELL CLONING; CELL FUNCTION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; GENE EDITING; GENE KNOCKOUT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; SINGLE CELL ANALYSIS; ANIMAL; CRISPR CAS SYSTEM; DEFICIENCY; DISEASE EXACERBATION; GENETICS; METABOLISM; METASTASIS; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DISEASE PROGRESSION; GENE EDITING; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN; PHENOTYPE; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS;

EID: 85048963608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0198790     Document Type: Article

References (44)

1. Guernet A, Grumolato L. CRISPR/Cas9 editing of the genome for cancer modeling. Methods. 2017; 121-122: 130-7. https://doi.org/10.1016/j.ymeth.2017.03.007 PMID: 28288827.
2. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPRCas9. Science. 2014; 346(6213): 1258096. https://doi.org/10.1126/science.1258096 PMID: 25430774.
3. Yang L, Yang JL, Byrne S, Pan J, Church GM. CRISPR/Cas9-Directed Genome Editing of Cultured Cells. Curr Protoc Mol Biol. 2014; 107: 31 1 1-17. https://doi.org/10.1002/0471142727.mb3101s107 PMID: 24984853.
4. Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017; 36(16): 2286-96. https://doi.org/10.1038/onc.2016.382 PMID: 27748765; PubMed Central PMCID: PMCPMC5245767.
5. Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, et al. Identifying drugtarget selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol. 2015; 22(1): 107-16. https://doi.org/10.1016/j.chembiol.2014.11.015 PMID: 25579209.
6. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121): 823-6. https://doi.org/10.1126/science.1232033 PMID: 23287722; PubMed Central PMCID: PMCPMC3712628.
7. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPRCas9 system. Nat Protoc. 2013; 8(11): 2281-308. https://doi.org/10.1038/nprot.2013.143 PMID: 24157548; PubMed Central PMCID: PMCPMC3969860.
8. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4): 613-28. https://doi.org/10.1016/j.cell.2017.01.018 PMID: 28187284.
9. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72 (19): 4875-82. Epub 2012/09/25. https://doi.org/10.1158/0008-5472.CAN-12-2217 PMID: 23002210; PubMed Central PMCID: PMC3712191.
10. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467): 338-45. https://doi.org/10.1038/nature12625 PMID: 24048066.
11. Laughney AM, Elizalde S, Genovese G, Bakhoum SF. Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic Evolution. Cell Rep. 2015; 12(5): 809-20. https://doi.org/10.1016/j.celrep.2015.06. 065 PMID: 26212324.
12. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4): 633-44. https://doi.org/10.1016/j.cell.2011.07.026 PMID: 21854987.
13. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013; 339(6119): 543-8. https://doi.org/10.1126/science.1227670 PMID: 23239622.
14. Goldberg DE, Siliciano RF, JacobsWR Jr. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell. 2012; 148(6): 1271-83. https://doi.org/10.1016/j.cell.2012.02.021 PMID: 22424234; PubMed Central PMCID: PMCPMC3322542.
15. Sanchez-Romero MA, Casadesus J. Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proc Natl Acad Sci U S A. 2014; 111(1): 355-60. https://doi.org/10.1073/pnas.1316084111 PMID: 24351930; PubMed Central PMCID: PMCPMC3890857.
16. Chait R, Palmer AC, Yelin I, Kishony R. Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environments. Nat Commun. 2016; 7: 10333. https://doi.org/10.1038/ncomms10333 PMID: 26787239; PubMed Central PMCID: PMCPMC4735756.
17. Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017; 355(6327): 826-30. https://doi.org/10.1126/science.aaj2191 PMID: 28183996.
18. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, et al. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis. 2005; 22(1): 47-59. https://doi.org/10.1007/s10585-005-2908-5 PMID: 16132578.
19. Campbell MJ, Wollish WS, Lobo M, Esserman LJ. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim. 2002; 38(6): 326-33. Epub 2003/01/07. https://doi.org/10.1290/1071-2690(2002)0382.0.CO;2 PMID: 12513120.
20. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008; 133(6): 994-1005. https://doi.org/10.1016/j.cell.2008.04.045 PMID: 18555776; PubMed Central PMCID: PMCPMC4121664.
21. Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, et al. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer. 2008; 8: 38. https://doi.org/10.1186/1471-2407-8-38 PMID: 18237408; PubMed Central PMCID: PMCPMC2259319.
22. Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer. 2009; 66 (2): 176-83. https://doi.org/10.1016/j.lungcan.2009.02.004 PMID: 19285749.
23. Jia R, Liang Y, Chen R, Liu G, Wang H, Tang M, et al. Osteopontin facilitates tumor metastasis by regulating epithelial-mesenchymal plasticity. Cell Death Dis. 2016; 7(12): e2564. https://doi.org/10.1038/cddis.2016.422 PMID: 28032860; PubMed Central PMCID: PMCPMC5261026.
24. Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, et al. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett. 2016; 383(2): 171-82. https://doi.org/10.1016/j.canlet.2016.09.033 PMID: 27702661.
25. Pang H, Cai L, Yang Y, Chen X, Sui G, Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm. 2011; 26(2): 165-73. https://doi.org/10.1089/cbr.2010.0838 PMID: 21539449.
26. Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 2014; 74(17): 4706-19. https://doi.org/10.1158/0008-5472. CAN-13-3334 PMID: 25035397.
27. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997; 3(4): 605-11. PMID: 9815727.
28. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007; 102(4): 859-68. https://doi.org/10.1002/jcb.21520 PMID: 17721886.
29. Xu YY, Zhang YY, Lu WF, Mi YJ, Chen YQ. Prognostic value of osteopontin expression in breast cancer: A meta-analysis. Mol Clin Oncol. 2015; 3(2): 357-62. https://doi.org/10.3892/mco.2014.480 PMID: 25798267; PubMed Central PMCID: PMCPMC4360850.
30. Luo SD, Chen YJ, Liu CT, Rau KM, Chen YC, Tsai HT, et al. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma. Biomed Res Int. 2015; 2015: 508587. https://doi.org/10.1155/2015/508587 PMID: 26491674; PubMed Central PMCID: PMCPMC4605257.
31. Ding K, Fan L, Chen S, Wang Y, Yu H, Sun Y, et al. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep. 2015; 34(6): 3297-303. https://doi.org/10.3892/or.2015.4306 PMID: 26397192.
32. Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer. Stem Cells Int. 2015; 2015: 247892. https://doi.org/10.1155/2015/247892 PMID: 26106421; PubMed Central PMCID: PMCPMC4461767.
33. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(20): 3271-7. https://doi.org/10.1200/JCO.2009.25.9820 PMID: 20498394.
34. Wei R, Wong JPC, Kwok HF. Osteopontin-A promising biomarker for cancer therapy. J Cancer. 2017; 8(12): 2173-83. https://doi.org/10.7150/jca.20480 PMID: 28819419; PubMed Central PMCID: PMCPMC5560134.
35. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, et al. Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006; 7(3): R19. https://doi.org/10.1186/gb-2006-7-3-r19 PMID: 16542501; PubMed Central PMCID: PMCPMC1557757.
36. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050): 518-24. https://doi.org/10.1038/nature03799 PMID: 16049480; PubMed Central PMCID: PMCPMC1283098.
37. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006; 9(2): 121-32. https://doi.org/10.1016/j.ccr.2006.01. 013 PMID: 16473279.
38. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25): 1999-2009. https://doi.org/10.1056/NEJMoa021967 PMID: 12490681.
39. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007; 133(9): 643-52. https://doi.org/10.1007/s00432-007-0215-z PMID: 17479289.
40. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010; 10(1): 71-81. PMID: 20205680.
41. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, et al. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog. 2005; 43(4): 225-36. https://doi.org/10.1002/mc.20105 PMID: 15864800.
42. Feng F, Rittling SR. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat. 2000; 63(1): 71-9. PMID: 11079161.
43. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005; 26(4): 741-51. https://doi.org/10.1093/carcin/bgi027 PMID: 15661802.
44. Wein L, Loi S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast. 2017; 34 Suppl 1: S27-S30. https://doi.org/10.1016/j.breast.2017.06.023 PMID: 28668293.